1. Exact generic ingredients and strengths in each listed brand
2. HbA1c-based treatment selection and escalation
3. Fasting versus post-meal hyperglycaemia: what it suggests and what to adjust
4. Dosing and titration of each drug class, including fixed-dose combinations
5. Practical example cases
6. Contraindications and precautions
7. Selection in CAD/IHD, post-PTCA, CKD, obesity, heart failure/ascites, liver disease, hypertension, stroke, sepsis, Parkinsonism, dyslipidaemia, and insulinoma
8. When insulin, rather than another oral combination, is appropriate

1. Exact generic ingredients and strengths in each listed brand
2. HbA1c-based treatment selection and escalation
3. Fasting versus post-meal hyperglycaemia: what it suggests and what to adjust
4. Dosing and titration of each drug class, including fixed-dose combinations
5. Practical example cases
6. Contraindications and precautions
7. Selection in CAD/IHD, post-PTCA, CKD, obesity, heart failure/ascites, liver disease, hypertension, stroke, sepsis, Parkinsonism, dyslipidaemia, and insulinoma
8. When insulin, rather than another oral combination, is appropriate

1. Brand-to-generic comparison
   • Glycomet GP 0.5/1/2/3 and Forte variants
   • Glycomet Trio Forte, GP-D
   • Janumet, Galvus Met, Jalra-M
   • Zita-Plus GM, Teneglyn-M-G
   • Amaryl M Forte, Obimet GX4, Dapabite
2. Core selection algorithm
   • HbA1c thresholds and when dual/triple therapy or insulin is appropriate
   • Why glucose pattern alone cannot select a drug
   • Targets for fasting and 2-hour post-meal glucose
3. Fasting versus post-meal hyperglycaemia
   • How to interpret a predominantly high FBS versus predominantly high PPBS
   • Which classes mainly affect each pattern
   • When “very high” glucose needs insulin evaluation rather than another oral fixed-dose combination
4. Drug-class dosing and titration
   • Metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, pioglitazone
   • Hypoglycaemia precautions and when not to escalate a fixed-dose combination
5. Case-based examples
   • Newly diagnosed disease
   • Obesity
   • CKD
   • Established CAD/post-PTCA
   • Elderly patient at hypoglycaemia risk
   • Marked fasting or post-meal hyperglycaemia
6. Contraindications and major cautions
   • Renal failure, heart failure/ascites, liver failure, sepsis, insulinoma, perioperative fasting, pancreatitis risk, and others
   • Reasons for each restriction
7. Comorbidity-based selection
   • IHD/CAD, hypertension, CKD, dyslipidaemia, obesity, CVA, ascites, Parkinsonism, liver failure, and post-CAG/PTCA.

1. Full adult T2DM clinical guide, in sections
2. Brand composition table first
3. HbA1c/FBS/PPBS decision algorithm first
4. Comorbidity and contraindications first
5. Case examples and titration first

Brand-to-generic composition table

Same drugs under different brands

Class-level clinical differences

HbA1c, FBS, and PPBS treatment algorithm for adults with type 2 diabetes

Step 1: Decide whether this is an urgent insulin situation

Do not keep adding oral fixed-dose combinations if any of these apply

• Polyuria, thirst, dehydration, vomiting, confusion, marked weakness
• Unintentional weight loss, ketosis, ketonuria, suspected type 1 diabetes, LADA, DKA, or HHS
• Acute sepsis, acute MI, stroke, severe infection, major surgery, or poor oral intake
• Random glucose or persistent glucose around ≥300 mg/dL
• HbA1c >10%
• Catabolic symptoms or glucose toxicity
• Failure of appropriately chosen dual/triple non-insulin treatment

Step 2: HbA1c-based starting and escalation algorithm

Step 3: Pattern-based use of FBS and PPBS

A. Predominantly high FBS

• FBS repeatedly >130 mg/dL
• PPBS may also be high
• HbA1c high
• Consider late dinner, high-carbohydrate dinner, missed medicine, steroid use, alcohol, illness, poor sleep, dawn phenomenon, or inadequate basal insulin if already using insulin.

1. First check adherence, meal timing, renal function, and whether current metformin dose is tolerated/appropriate.
2. Metformin generally helps fasting glucose by reducing hepatic glucose production.
3. Sulfonylureas such as glimepiride can reduce fasting and post-meal glucose, but bring hypoglycaemia and weight-gain risk.
4. DPP-4 inhibitors such as sitagliptin, vildagliptin, and teneligliptin have modest glucose-lowering effect with low intrinsic hypoglycaemia risk.
5. SGLT2 inhibitors such as dapagliflozin lower glucose independently of insulin and may help weight/BP, but are not appropriate in all eGFR ranges or acute illness.
6. If fasting glucose remains very high despite sensible oral treatment, basal insulin is often more rational than continually increasing glimepiride.

B. Predominantly high PPBS

• FBS/premeal glucose is near target, usually 80-130 mg/dL
• PPBS repeatedly >180 mg/dL
• HbA1c still above target
• Large carbohydrate portions, sweet drinks, refined rice/flour, missed breakfast/lunch medicine, steroid use, or poor meal composition may be central causes.

1. Confirm timing: PPBS should be measured 1-2 hours after starting the meal, not from finishing it.
2. Correct meal composition and carbohydrate quantity first.
3. Voglibose preferentially targets post-meal glucose excursions by delaying carbohydrate absorption. It is the extra component in Glycomet Trio Forte.
4. DPP-4 inhibitors can modestly improve meal-related glucose with low hypoglycaemia risk. Examples: sitagliptin in Janumet, vildagliptin in Galvus Met/Jalra-M, teneligliptin in Teneglyn formulations.
5. GLP-1 receptor agonist or a rapid-acting mealtime insulin may be more appropriate for severe or persistent post-meal excursions, depending on the full clinical setting.
6. Glimepiride may lower PPBS but can cause delayed hypoglycaemia, particularly if meals are skipped or food intake is inconsistent.

C. Both FBS and PPBS are high

• FBS >130 mg/dL and PPBS >180 mg/dL repeatedly
• HbA1c above target

• Check adherence, diet, steroids, infection, renal/liver function, and incorrect tablet use.
• If HbA1c is modestly above goal and patient stable: optimize or move to rational dual therapy.
• If HbA1c is >1.5% above the individual target: generally use combination therapy, selected by comorbidity rather than simply adding a sulfonylurea.
• If HbA1c is ≥10%, glucose is ≥300 mg/dL, or symptoms/catabolism are present: assess for insulin.

How the listed brands fit the algorithm

1. Glimepiride + metformin combinations

• Cost-sensitive patient
• Adequate endogenous insulin secretion
• Regular, reliable meals
• Low risk of severe hypoglycaemia
• No problematic renal/hepatic impairment
• A need for greater HbA1c reduction than metformin alone

• Recurrent hypoglycaemia
• Irregular meals, fasting, food insecurity, frailty
• Elderly person at fall risk
• Advanced CKD or significant liver disease
• Obesity where weight gain is undesirable
• Known insulinoma or unexplained recurrent fasting hypoglycaemia

2. Metformin + DPP-4 inhibitor combinations

• Mild to moderate hyperglycaemia
• Person at high hypoglycaemia risk
• Older adult with unpredictable food intake
• Weight-neutral approach desired
• Need to avoid sulfonylurea

• HbA1c lowering is more modest than sulfonylurea or insulin in many people.
• Metformin still needs eGFR-based assessment.
• Sitagliptin requires renal dose adjustment.
• Vildagliptin requires attention to liver enzymes and should be avoided in significant hepatic impairment.

3. Metformin + glimepiride + voglibose

• FBS and PPBS are both elevated
• Particularly prominent carbohydrate-related post-meal excursions
• Patient is already tolerating metformin and glimepiride
• No major hypoglycaemia risk

• Recurrent hypoglycaemia or irregular meals, because of glimepiride
• Significant gastrointestinal intolerance
• Significant renal or liver impairment, as alpha-glucosidase inhibitors may be unsuitable
• Very high HbA1c/glucose with symptoms, where insulin evaluation is more appropriate

4. Triple combinations containing a DPP-4 inhibitor + glimepiride + metformin

• Patient genuinely needs triple therapy
• There is no unacceptable hypoglycaemia risk
• eGFR and liver status permit the specific components
• Patient has not reached goal on appropriately dosed dual therapy

• These combinations can conceal excessive sulfonylurea exposure.
• They are not automatically preferable to a cardioprotective SGLT2 inhibitor or GLP-1-based therapy in CAD, heart failure, CKD, or obesity.
• Avoid arbitrary tablet escalation without knowing exactly how much glimepiride, metformin, and DPP-4 inhibitor the patient receives per day.

5. Dapagliflozin-containing therapy

• Type 2 diabetes with heart failure, CKD, or established ASCVD where an SGLT2 inhibitor may offer organ protection
• Overweight/obesity
• Mild hypertension, if volume status is stable
• Need for a low-hypoglycaemia option

• DKA or suspected DKA
• Acute sepsis, dehydration, vomiting, prolonged fasting, or major surgery
• Significant active genital infection
• Very low eGFR depending on indication and local product label
• High risk of euglycaemic ketoacidosis

Practical review cycle

1. Before prescribing/changing treatment
   • HbA1c
   • FBS and 1-2-hour PPBS log, ideally 3-7 days minimum
   • eGFR/creatinine, urine albumin-creatinine ratio
   • AST/ALT and bilirubin when indicated
   • Weight/BMI, BP, lipids
   • Hypoglycaemia history
   • Current tablets, actual dose, timing, and adherence
   • ASCVD, HF, CKD, retinopathy, neuropathy, foot disease
   • Pregnancy possibility where relevant
2. After a change
   • Review SMBG/CGM, hypoglycaemia, hydration, diet, adverse effects in about 2-4 weeks when clinically appropriate.
   • Recheck HbA1c in about 3 months, or earlier if severe hyperglycaemia, treatment side effects, or insulin initiation demands closer monitoring.
3. If treatment fails
   • Do not assume drug failure before checking adherence, steroid exposure, infection, food pattern, dose timing, renal decline, and whether the diagnosis is actually type 2 diabetes.
   • Avoid stacking multiple medications that all cause hypoglycaemia, especially sulfonylurea plus insulin, without a clear plan.

HbA1c context

Topic map

1. Absolute contraindications and major cautions by class
   • Metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, alpha-glucosidase inhibitors, pioglitazone, and insulin.
2. Comorbidity-based drug selection
   • CAD/IHD and post-CAG/PTCA
   • Heart failure, ascites, hypertension, obesity, dyslipidaemia
   • CKD and liver failure
   • CVA/stroke, Parkinsonism, sepsis, insulinoma, perioperative fasting
3. Practical dose and titration guide
   • Starting doses, dose increments, monitoring, and how to safely use or avoid fixed-dose combinations.
4. Case-based examples
   • New T2DM, obesity, CKD, ASCVD/post-PTCA, older adult with hypoglycaemia risk, and high fasting versus high post-meal glucose.
5. Brand-to-generic reconciliation
   • Verify uncertain combinations and prevent duplicate metformin, glimepiride, DPP-4 inhibitor, or SGLT2 inhibitor exposure.

1. Exact generic ingredients and strengths in each listed brand
2. HbA1c-based treatment selection and escalation
3. Fasting versus post-meal hyperglycaemia: what it suggests and what to adjust
4. Dosing and titration of each drug class, including fixed-dose combinations
5. Practical example cases
6. Contraindications and precautions
7. Selection in CAD/IHD, post-PTCA, CKD, obesity, heart failure/ascites, liver disease, hypertension, stroke, sepsis, Parkinsonism, dyslipidaemia, and insulinoma
8. When insulin, rather than another oral combination, is appropriate

1. Brand-to-generic comparison
   • Glycomet GP 0.5/1/2/3 and Forte variants
   • Glycomet Trio Forte, GP-D
   • Janumet, Galvus Met, Jalra-M
   • Zita-Plus GM, Teneglyn-M-G
   • Amaryl M Forte, Obimet GX4, Dapabite
2. Core selection algorithm
   • HbA1c thresholds and when dual/triple therapy or insulin is appropriate
   • Why glucose pattern alone cannot select a drug
   • Targets for fasting and 2-hour post-meal glucose
3. Fasting versus post-meal hyperglycaemia
   • How to interpret a predominantly high FBS versus predominantly high PPBS
   • Which classes mainly affect each pattern
   • When “very high” glucose needs insulin evaluation rather than another oral fixed-dose combination
4. Drug-class dosing and titration
   • Metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, pioglitazone
   • Hypoglycaemia precautions and when not to escalate a fixed-dose combination
5. Case-based examples
   • Newly diagnosed disease
   • Obesity
   • CKD
   • Established CAD/post-PTCA
   • Elderly patient at hypoglycaemia risk
   • Marked fasting or post-meal hyperglycaemia
6. Contraindications and major cautions
   • Renal failure, heart failure/ascites, liver failure, sepsis, insulinoma, perioperative fasting, pancreatitis risk, and others
   • Reasons for each restriction
7. Comorbidity-based selection
   • IHD/CAD, hypertension, CKD, dyslipidaemia, obesity, CVA, ascites, Parkinsonism, liver failure, and post-CAG/PTCA.

1. Full adult T2DM clinical guide, in sections
2. Brand composition table first
3. HbA1c/FBS/PPBS decision algorithm first
4. Comorbidity and contraindications first
5. Case examples and titration first## Brand-to-generic composition table

Same drugs under different brands

Class-level clinical differences

Step 1: Decide whether this is an urgent insulin situation

Do not keep adding oral fixed-dose combinations if any of these apply

• Polyuria, thirst, dehydration, vomiting, confusion, marked weakness
• Unintentional weight loss, ketosis, ketonuria, suspected type 1 diabetes, LADA, DKA, or HHS
• Acute sepsis, acute MI, stroke, severe infection, major surgery, or poor oral intake
• Random glucose or persistent glucose around ≥300 mg/dL
• HbA1c >10%
• Catabolic symptoms or glucose toxicity
• Failure of appropriately chosen dual/triple non-insulin treatment

Step 2: HbA1c-based starting and escalation algorithm

Step 3: Pattern-based use of FBS and PPBS

A. Predominantly high FBS

• FBS repeatedly >130 mg/dL
• PPBS may also be high
• HbA1c high
• Consider late dinner, high-carbohydrate dinner, missed medicine, steroid use, alcohol, illness, poor sleep, dawn phenomenon, or inadequate basal insulin if already using insulin.

1. First check adherence, meal timing, renal function, and whether current metformin dose is tolerated/appropriate.
2. Metformin generally helps fasting glucose by reducing hepatic glucose production.
3. Sulfonylureas such as glimepiride can reduce fasting and post-meal glucose, but bring hypoglycaemia and weight-gain risk.
4. DPP-4 inhibitors such as sitagliptin, vildagliptin, and teneligliptin have modest glucose-lowering effect with low intrinsic hypoglycaemia risk.
5. SGLT2 inhibitors such as dapagliflozin lower glucose independently of insulin and may help weight/BP, but are not appropriate in all eGFR ranges or acute illness.
6. If fasting glucose remains very high despite sensible oral treatment, basal insulin is often more rational than continually increasing glimepiride.

B. Predominantly high PPBS

• FBS/premeal glucose is near target, usually 80-130 mg/dL
• PPBS repeatedly >180 mg/dL
• HbA1c still above target
• Large carbohydrate portions, sweet drinks, refined rice/flour, missed breakfast/lunch medicine, steroid use, or poor meal composition may be central causes.

1. Confirm timing: PPBS should be measured 1-2 hours after starting the meal, not from finishing it.
2. Correct meal composition and carbohydrate quantity first.
3. Voglibose preferentially targets post-meal glucose excursions by delaying carbohydrate absorption. It is the extra component in Glycomet Trio Forte.
4. DPP-4 inhibitors can modestly improve meal-related glucose with low hypoglycaemia risk. Examples: sitagliptin in Janumet, vildagliptin in Galvus Met/Jalra-M, teneligliptin in Teneglyn formulations.
5. GLP-1 receptor agonist or a rapid-acting mealtime insulin may be more appropriate for severe or persistent post-meal excursions, depending on the full clinical setting.
6. Glimepiride may lower PPBS but can cause delayed hypoglycaemia, particularly if meals are skipped or food intake is inconsistent.

C. Both FBS and PPBS are high

• FBS >130 mg/dL and PPBS >180 mg/dL repeatedly
• HbA1c above target

• Check adherence, diet, steroids, infection, renal/liver function, and incorrect tablet use.
• If HbA1c is modestly above goal and patient stable: optimize or move to rational dual therapy.
• If HbA1c is >1.5% above the individual target: generally use combination therapy, selected by comorbidity rather than simply adding a sulfonylurea.
• If HbA1c is ≥10%, glucose is ≥300 mg/dL, or symptoms/catabolism are present: assess for insulin.

How the listed brands fit the algorithm

1. Glimepiride + metformin combinations

• Cost-sensitive patient
• Adequate endogenous insulin secretion
• Regular, reliable meals
• Low risk of severe hypoglycaemia
• No problematic renal/hepatic impairment
• A need for greater HbA1c reduction than metformin alone

• Recurrent hypoglycaemia
• Irregular meals, fasting, food insecurity, frailty
• Elderly person at fall risk
• Advanced CKD or significant liver disease
• Obesity where weight gain is undesirable
• Known insulinoma or unexplained recurrent fasting hypoglycaemia

2. Metformin + DPP-4 inhibitor combinations

• Mild to moderate hyperglycaemia
• Person at high hypoglycaemia risk
• Older adult with unpredictable food intake
• Weight-neutral approach desired
• Need to avoid sulfonylurea

• HbA1c lowering is more modest than sulfonylurea or insulin in many people.
• Metformin still needs eGFR-based assessment.
• Sitagliptin requires renal dose adjustment.
• Vildagliptin requires attention to liver enzymes and should be avoided in significant hepatic impairment.

3. Metformin + glimepiride + voglibose

• FBS and PPBS are both elevated
• Particularly prominent carbohydrate-related post-meal excursions
• Patient is already tolerating metformin and glimepiride
• No major hypoglycaemia risk

• Recurrent hypoglycaemia or irregular meals, because of glimepiride
• Significant gastrointestinal intolerance
• Significant renal or liver impairment, as alpha-glucosidase inhibitors may be unsuitable
• Very high HbA1c/glucose with symptoms, where insulin evaluation is more appropriate

4. Triple combinations containing a DPP-4 inhibitor + glimepiride + metformin

• Patient genuinely needs triple therapy
• There is no unacceptable hypoglycaemia risk
• eGFR and liver status permit the specific components
• Patient has not reached goal on appropriately dosed dual therapy

• These combinations can conceal excessive sulfonylurea exposure.
• They are not automatically preferable to a cardioprotective SGLT2 inhibitor or GLP-1-based therapy in CAD, heart failure, CKD, or obesity.
• Avoid arbitrary tablet escalation without knowing exactly how much glimepiride, metformin, and DPP-4 inhibitor the patient receives per day.

5. Dapagliflozin-containing therapy

• Type 2 diabetes with heart failure, CKD, or established ASCVD where an SGLT2 inhibitor may offer organ protection
• Overweight/obesity
• Mild hypertension, if volume status is stable
• Need for a low-hypoglycaemia option

• DKA or suspected DKA
• Acute sepsis, dehydration, vomiting, prolonged fasting, or major surgery
• Significant active genital infection
• Very low eGFR depending on indication and local product label
• High risk of euglycaemic ketoacidosis

Practical review cycle

1. Before prescribing/changing treatment
   • HbA1c
   • FBS and 1-2-hour PPBS log, ideally 3-7 days minimum
   • eGFR/creatinine, urine albumin-creatinine ratio
   • AST/ALT and bilirubin when indicated
   • Weight/BMI, BP, lipids
   • Hypoglycaemia history
   • Current tablets, actual dose, timing, and adherence
   • ASCVD, HF, CKD, retinopathy, neuropathy, foot disease
   • Pregnancy possibility where relevant
2. After a change
   • Review SMBG/CGM, hypoglycaemia, hydration, diet, adverse effects in about 2-4 weeks when clinically appropriate.
   • Recheck HbA1c in about 3 months, or earlier if severe hyperglycaemia, treatment side effects, or insulin initiation demands closer monitoring.
3. If treatment fails
   • Do not assume drug failure before checking adherence, steroid exposure, infection, food pattern, dose timing, renal decline, and whether the diagnosis is actually type 2 diabetes.
   • Avoid stacking multiple medications that all cause hypoglycaemia, especially sulfonylurea plus insulin, without a clear plan.

HbA1c context

1. Absolute contraindications and major cautions by class
   • Metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, alpha-glucosidase inhibitors, pioglitazone, and insulin.
2. Comorbidity-based drug selection
   • CAD/IHD and post-CAG/PTCA
   • Heart failure, ascites, hypertension, obesity, dyslipidaemia
   • CKD and liver failure
   • CVA/stroke, Parkinsonism, sepsis, insulinoma, perioperative fasting
3. Practical dose and titration guide
   • Starting doses, dose increments, monitoring, and how to safely use or avoid fixed-dose combinations.
4. Case-based examples
   • New T2DM, obesity, CKD, ASCVD/post-PTCA, older adult with hypoglycaemia risk, and high fasting versus high post-meal glucose.
5. Brand-to-generic reconciliation
   • Verify uncertain combinations and prevent duplicate metformin, glimepiride, DPP-4 inhibitor, or SGLT2 inhibitor exposure.

1. Contraindications by drug class
2. Comorbidity-based selection
3. Dose and titration
4. Case examples
5. Brand safety and duplicate-drug check

Practical adult T2DM case examples

Case 1: Newly diagnosed, mild hyperglycaemia, no comorbidity

• Age 45 years, BMI 26 kg/m²
• HbA1c 7.4%
• FBS 132-145 mg/dL
• PPBS 175-195 mg/dL
• eGFR 92 mL/min/1.73 m², LFT normal
• No CAD, CKD, HF, recurrent hypoglycaemia, or weight-loss concern

• HbA1c is only modestly above the usual target.
• First determine diet pattern, physical activity, alcohol intake, sleep, steroid use, and readiness for lifestyle treatment.
• A two- or three-drug fixed-dose combination is usually unnecessary at the outset.

• Metformin alone is often appropriate if tolerated and renal function permits.
• Common educational titration: start metformin 500 mg with the evening meal, then increase gradually every 1-2 weeks as tolerated toward an effective dose, often 1,500-2,000 mg/day, subject to eGFR and gastrointestinal tolerance.
• Use an SR/ER preparation if gastrointestinal adverse effects limit immediate-release metformin.

• Glycomet-GP, Amaryl M Forte, or Obimet GX, because these add glimepiride and increase hypoglycaemia risk without a clear initial need.
• Glycomet Trio Forte, since triple therapy is disproportionate for this profile.

• SMBG pattern within 2-4 weeks if being used.
• HbA1c in roughly 3 months.

Case 2: High PPBS with near-target FBS

• Age 52 years
• Taking metformin 1,000 mg/day reliably
• HbA1c 7.8%
• FBS 100-118 mg/dL
• PPBS 230-270 mg/dL after rice-heavy meals
• eGFR 80, BMI 24, no ASCVD/HF/CKD

• Fasting control is near target.
• The main issue is post-meal carbohydrate excursion, not simply a need to raise every diabetes medicine.
• Confirm that PPBS was tested 1-2 hours from the beginning of the meal.

1. Reduce refined carbohydrate load and sweetened drinks.
2. Ask about medicine timing and meal regularity.
3. Review 3-7 days of paired premeal and post-meal values.

• A DPP-4 inhibitor plus metformin can be a lower-hypoglycaemia option. Examples:
  • Janumet: sitagliptin + metformin
  • Galvus Met or Jalra-M: vildagliptin + metformin
• If the clinician specifically needs an alpha-glucosidase inhibitor for meal-related glucose excursions, voglibose is an option. Glycomet Trio Forte adds voglibose, but it also contains glimepiride, so it is not merely a “PPBS tablet.”

• Glycomet-GP 2/3 or Obimet GX4 if fasting is already controlled and the patient skips meals or has hypoglycaemia risk.
• A higher glimepiride dose can lower PPBS but also causes hypoglycaemia and weight gain.

• If FBS is controlled but HbA1c remains high, target PPBS and lifestyle pattern before simply intensifying a fasting-oriented treatment.

Case 3: Predominantly high FBS

• Age 55 years
• Metformin 500 mg twice daily
• HbA1c 8.1%
• FBS 175-210 mg/dL
• PPBS 210-250 mg/dL
• eGFR 74, LFT normal
• No established ASCVD, HF, or CKD
• Eats regular meals and has no prior hypoglycaemia

• Both fasting and post-meal glucose are elevated, with fasting particularly problematic.
• Before adding medicine: assess adherence, late dinners, alcohol, steroid use, infection, sleep, and missed doses.

• If metformin is tolerated, optimize it first if not already at a useful dose.
• If a low-cost approach is required and hypoglycaemia risk is low, a glimepiride-metformin combination may be considered, for example a GP 0.5/1 strength rather than jumping straight to GP 2 or GP 3.
• The glimepiride component should be titrated conservatively, with glucose logs and hypoglycaemia education.

• Do not increase a fixed-dose GP tablet if the desired change is only in metformin or only in glimepiride. For example:
  • GP 2 versus GP 2 Forte changes metformin strength substantially.
  • Moving from GP 1 to GP 2 increases glimepiride exposure.
• In a real patient, separate components may sometimes allow safer titration than a fixed-dose combination.

• Consider whether basal insulin is a more logical next step than repeated sulfonylurea escalation, particularly when glucose is persistently very high.

Case 4: Obesity and hypertension, no established ASCVD

• Age 42 years, BMI 35 kg/m²
• HbA1c 8.6%
• FBS 155 mg/dL, PPBS 240 mg/dL
• BP 148/92 mmHg
• eGFR 88, urine ACR normal
• No heart failure or recurrent genital infections

• Weight reduction and avoiding hypoglycaemia/weight-promoting drugs are major priorities.
• A sulfonylurea-heavy path may improve glucose but can cause weight gain.

• Metformin, if tolerated and not contraindicated.
• Consider adding an SGLT2 inhibitor, such as dapagliflozin, if clinically eligible. It is represented by Dapabite and may also be included in some Glycomet-GP D packs.
• A GLP-1 receptor agonist or dual GIP/GLP-1 agent may be preferable where available, affordable, and appropriate because of larger weight benefit.

• Glimepiride-based GP/Forte/Obimet/Amaryl combinations if recurrent hypoglycaemia, weight gain, or irregular eating is likely.
• Pioglitazone-containing treatment when weight gain or edema is a problem.

• Maintain hydration.
• Recognize genital symptoms early.
• Withhold temporarily in prolonged fasting, severe illness, vomiting, dehydration, or before surgery according to local protocol because of ketoacidosis risk.

Case 5: Established CAD, post-PTCA

• Age 63 years
• Prior MI and PTCA with stent
• HbA1c 7.9%
• FBS 145 mg/dL, PPBS 205 mg/dL
• eGFR 68, no active heart failure
• Currently taking metformin and a low-dose glimepiride combination

• This is not just a glucose-number case. Established ASCVD changes the preferred class.
• Review statin, antiplatelet plan, BP, smoking, weight, renal function, and cardiac symptoms alongside HbA1c.

• Consider an SGLT2 inhibitor with cardiovascular benefit and/or a GLP-1 receptor agonist with demonstrated cardiovascular benefit, according to individual suitability and availability.
• If adding dapagliflozin, check whether the current brand already includes an SGLT2 inhibitor. Do not duplicate it.
• Reassess whether glimepiride is still needed, particularly if hypoglycaemia risk or weight gain is problematic.

• Pioglitazone in a patient with symptomatic heart failure or edema.
• Escalating glimepiride solely because it is inexpensive, if the patient has recurrent hypoglycaemia or high cardiovascular risk.

Case 6: CKD with albuminuria

• Age 60 years
• eGFR 38 mL/min/1.73 m²
• Urine ACR 650 mg/g
• HbA1c 8.0%
• FBS 145-170 mg/dL
• PPBS 210-230 mg/dL
• Taking Glycomet-GP 2 Forte

• Fixed-dose glimepiride-metformin therapy is potentially unsuitable because:
  • Metformin requires eGFR-based dose review and should generally not be used when eGFR is <30.
  • Sulfonylurea-associated hypoglycaemia risk rises in CKD.
  • The fixed combination makes it hard to adjust one component safely.

1. Review the actual daily metformin amount and eGFR trend.
2. Stop or reduce components only under clinician supervision, not by self-adjustment.
3. In eligible albuminuric CKD, prioritize an SGLT2 inhibitor for kidney and cardiovascular protection if eGFR and clinical status allow.
4. If further glycaemic lowering is needed and metformin is no longer suitable, a renal-appropriate DPP-4 inhibitor or GLP-1-based therapy may be considered.
5. Insulin may be needed, but doses require caution because reduced renal clearance can increase hypoglycaemia risk.

• Casual increase from GP 2 Forte to a higher GP or Obimet GX4.
• Dehydration, NSAID overuse, and unmonitored “sick-day” use of glucose-lowering medication.

Case 7: Elderly patient, irregular meals, recurrent hypoglycaemia

• Age 78 years, lives alone
• HbA1c 7.2%
• FBS 95-115 mg/dL
• Several readings of 55-65 mg/dL before lunch
• Taking Glycomet-GP 2 Forte
• eGFR 48, weight loss, appetite poor

• HbA1c looks “good,” but it is unsafe because it includes frequent hypoglycaemia.
• A more relaxed HbA1c goal may be appropriate depending on frailty, comorbidities, cognition, and life expectancy.

• Do not increase therapy.
• The priority is deintensification, often reducing or stopping the sulfonylurea component under supervision.
• Consider a lower-hypoglycaemia regimen, such as appropriately adjusted metformin if renal function permits, or a DPP-4 inhibitor selected and dosed according to kidney function.
• Simplify regimen and ensure the patient has a plan for missed meals and low glucose.

• Glimepiride dose escalation.
• High-strength fixed-dose GP/Obimet/Amaryl combinations.
• “Chasing” HbA1c <7% in a person at high hypoglycaemia/fall risk.

Case 8: Very high glucose with symptoms

• Age 50 years, newly diagnosed
• HbA1c 11.8%
• FBS 315 mg/dL, PPBS 420 mg/dL
• Polyuria, thirst, 6-kg unintentional weight loss, fatigue
• Urine ketones pending

• This may represent severe insulin deficiency or glucose toxicity.
• Type 1 diabetes, LADA, DKA, HHS, infection, or pancreatic disease must be considered.
• This is not a situation for choosing between GP 2 Forte, Trio Forte, Janumet, or Teneglyn-M-G in routine outpatient fashion.

• Same-day in-person assessment.
• Check capillary/serum ketones, electrolytes, bicarbonate, renal function, hydration status, infection markers, and acid-base status as indicated.
• Insulin is often appropriate initially, sometimes temporarily, until symptoms and glucose toxicity improve.
• Once stable, reassess the diagnosis and longer-term regimen.

• Add multiple oral tablets without assessment.
• Use an SGLT2 inhibitor if ketosis is suspected.
• Delay emergency evaluation if vomiting, abdominal pain, deep breathing, confusion, severe dehydration, or drowsiness occurs.

Quick pattern-to-action summary